Friday, July 22, 2022
BioSig Technologies (BSGM)
BioSig Announces Real World PURE EP Physician-Initiated Research
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(TM) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Announced study tests real-world AF patients. BioSig announced yesterday a physician-initiated study. The research will study 30 patients with de novo paroxysmal atrial fibrillation (AF) undergoing pulmonary vein isolation (PVI), with 6 month and 12 month follow-up. While the PURE EP 2.0 trial assessed PURE EP signal quality vs. current technology, this is the first real world study of patient outcomes. To date there have been few human trials that test the durability of PVI AF procedures. The study is officially registered at clincaltrials.gov NCT05464537 .
Kansas City Heart Rhythm Research Foundation is conducting the study. Recall that Kansas City Heart Rhythm Institute at Overland Park Regional Medical Center recently purchased the PURE EP System. Dhanunjaya DJ Lakkireddy, MD, Medical Director for the Kansas City Heart Rhythm Institute, is initiating this research protocol analyzing the signals acquired by the PURE EP System during RF ablation. Long lasting, contiguous and deep enough ablation lesions have been and are a clinical challenge due to thickness of atrial tissue in different regions, as well as factors like the power and contact force of the ablation catheter. AF ablation procedures might need to be repeated if the ablated tissue does not prevent recurrence of AF. PURE EP signal processing will be reviewed for helping produce more durable, quicker and cost-effective outcomes….
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
